SURPASS-3 STUDY/ GOG-3084
Research type
Research Study
Full title
A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICALTRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084)
IRAS ID
1007284
Contact name
Eric Dollins
Contact email
Sponsor organisation
Adaptimmune LLC
Eudract number
2022-003176-16
Clinicaltrials.gov Identifier
Research summary
ADP-0055-003 is a clinical trial to evaluate if Adaptimmune T-cell therapy, ADP-A2M4CD8 works in ovarian cancer and is safe. ADP-A2M4CD8 is the patient's changed immune cells (T-cells) to target and attack cancer cells. Patients will receive ADP-A2M4CD8 with or without nivolumab. Patients are selected at random (by chance) to receive Nivolumab. Nivolumab is approved in various cancers.
Patients with ovarian cancer are typically treated with surgery and chemotherapy. Some will receive chemotherapy alone. After receiving the first treatment, ovarian cancer usually returns in about 80% of patients. There is a need for effective ovarian cancer treatments.
Patients will enrol into this clinical trial after chemotherapy has stopped working for them.
One study using ADP-A2M4CD8 has shown benefit in ovarian cancer. In this study, patients will be assessed to determine which treatment: ADP-A2M4CD8 alone or a combination of nivolumab + ADP-A2M4CD8, shows a better benefit for patients with recurrent ovarian cancer. The safety of both treatments will be monitored and assessed to ensure that they have an acceptable risk.REC name
London - West London & GTAC Research Ethics Committee
REC reference
23/LO/0629
Date of REC Opinion
17 Oct 2023
REC opinion
Further Information Favourable Opinion